Search 

Novodiax has develop a technology platform and product line that address unmet needs for rapid and accurate cancer diagnosis, including rapid intraoperative diagnosis for surgical treatments of cancers, rapid presurgical cancer diagnosis through biopsy specimens (Rapid On-Site Evaluation, ROSE), rapid disease diagnosis through liquid biopsy specimens and novel cancer biomarker’s based companion diagnostics (CDx).

Novodiax pioneered a 10-minute ihcDirectTM IHC detection for frozen section technology, which significantly saves time and reduces reagent consumption and costs with easy to use by reducing steps from traditional protocols. This innovated technology has removed many of the time constraining barriers that once prevented application of IHC stains in intraoperative diagnosis and Mohs surgery labs.
Novodiax also provides multiplex IHC detection which accelerates turnaround time, increases instrument productivity and reduces reagent consumption.

In summary Novodiax enjoys the following major strength
1- Novodiax currently offers a 10 min IHC product line that can be used for intraoperative evaluation of frozen tissues and for Rapid On-Site Evaluation (ROSE) of biopsy specimens.
2- Novodiax will launch in Q4 2020 an advanced automation system including a rapid compact IHC stainer and a superfast FFPE tissue pre-treatment device along with tens of ihcDirect® IHC reagents. This affordable system is a perfect solution for any situation where a rapid turnaround time is needed, such as, the rush cases using FFPE tissues in large medical centers. Our 10 min intraoperative and ROSE protocols will be available on the system too.
3- Novodiax products have already been optimized for Leica staining instruments and can be optimized for all automated staining platforms in the market.
4- The rapid turnaround time of Novodiax’s reagents and instruments offers a natural advantage for multiplex applications.

VC focused on healthcare industry

Private investment firm

PCS provides new product engineering and design services for medical device and Medtech companies. We have served enterprise and entrepreneurs for over two decades and our QMS is ISO13485:2016 certified.

Multi cancer early detection screening diagnostic solutions (liquid biopsy)

Usurpo are a UK based specialist search firm focused on helping high-growth Life Sciences businesses hire outstanding executives worldwide. We have successfully run search campaigns in EMEA, ASIA PAC, India and the US.

We work closely with Pharmaceutical, Biotechnology, Medical Device companies and service providers to help them build exceptional leadership teams, particularly across Europe and the US. We have a track record of helping international business from China, Japan, Israel and Korea make key hires in the US and Europe for their expanding international teams.

We help our clients to hire Senior Director, VP and C-suite level professionals into the following areas:

- Clinical Development (Chief Medical Officer, Chief Development Officer, Medical Director, Therapeutic area experts)
- Regulatory Affairs
- CMC
- Business Development (Licensing, M&A, Corporate Development)
- Business Development (Sales and business expansion for service providers)
- Cross functional C-suite leadership
- Sales and Marketing leaders

Guangzhou Wondfo Biotech Co., Ltd., headquartered in Guangzhou science city, has been focusing on the R&D, production, sales and service of point-of-care testing (POCT) products and providing customers with professional rapid diagnosis and chronic disease management solutions since founded in 1992. Wondfo now has more than 3000 employees and a wide range of products for the rapid identification of cardiovascular diseases, inflammation, tumor, infectious diseases, drug abuse, pregnancy, and so on, widely sold to 140+ countries and regions.

上海元亨祥股权投资基金集团有限公司（简称“元亨祥基金”），2012年8月落户于上海陆家嘴国际金融中心，2014年4月在中国证券投资基金业协会登记为“私募基金管理人”，下设元杏资产（其他类私募基金）、祥乾投资（股权类私募基金）、王道资产（证券类私募基金）。

作为风控型资产管理专家，元亨祥基金始终秉承“专业创造价值，安全方得安心”的品牌理念，顺应国家发展战略，携手世界500强名企太平洋建设、中国建筑、中冶天工等交易对手，积极引导社会资本投资“大基建、大康养、大文旅”领域，累计投资项目超过300个、累计投资规模超过300亿、累计撬动项目总规模超过3000亿，投资足迹遍布全国；同时，凭借投向明确、风控周密、期限合理、业绩领先、产品丰富五大优势，持续专注做好基建投资基金、证券投资基金、特色小镇基金、不动产基金、产业投资基金五大系列基金，为客户倾力打造专属投融资服务。